Delcath Systems, Inc. (DCTH)

NASDAQ: DCTH · IEX Real-Time Price · USD
3.86
+0.20 (5.46%)
Feb 6, 2023, 2:22 PM EST - Market open
5.46%
Market Cap 39.18M
Revenue (ttm) 4.19M
Net Income (ttm) -31.71M
Shares Out 10.05M
EPS (ttm) -3.76
PE Ratio n/a
Forward PE n/a
Dividend n/a
Ex-Dividend Date n/a
Volume 44,826
Open 3.78
Previous Close 3.66
Day's Range 3.78 - 3.89
52-Week Range 2.34 - 7.75
Beta 1.05
Analysts Buy
Price Target 17.75 (+359.85%)
Earnings Date Mar 23, 2023

About DCTH

Delcath Systems, Inc., an interventional oncology company, focuses on the treatment of primary and metastatic liver cancers in the United States and Europe. The company's lead product candidate is HEPZATO KIT, a melphalan hydrochloride for injection/hepatic delivery system to administer high-dose chemotherapy to the liver while controlling systemic exposure and associated side effects. Its clinical development program for HEPZATO is the FOCUS clinical trial for patients with hepatic dominant ocular melanoma to investigate objective response rat... [Read more]

Industry Medical Devices
Sector Healthcare
Founded 1988
Employees 55
Stock Exchange NASDAQ
Ticker Symbol DCTH
Full Company Profile

Financial Performance

In 2021, DCTH's revenue was $3.56 million, an increase of 115.98% compared to the previous year's $1.65 million. Losses were -$25.65 million, 5.94% more than in 2020.

Financial Statements

Analyst Forecast

According to 11 analysts, the average rating for DCTH stock is "Buy." The 12-month stock price forecast is $17.75, which is an increase of 359.85% from the latest price.

Price Target
$17.75
(359.85% upside)
Analyst Consensus: Buy
Stock Forecasts

News

Delcath Systems to Participate at the BTIG MedTech, Digital Health, Life Sciences & Diagnostic Tools Conference on February 14 to 16

NEW YORK , Jan. 30, 2023 /PRNewswire/ -- Delcath Systems, Inc. (Nasdaq: DCTH), an interventional oncology company focused on the treatment of primary and metastatic cancers of the liver, will particip...

1 week ago - PRNewsWire

Delcath Systems Announces Updated Results from CHOPIN Phase 1b Trial Published in Cardiovascular and Interventional Radiology

Updated results in seven patients with advanced uveal melanoma treated with CHEMOSAT and ipilimumab plus nivolumab show a Median PFS of 29.1 months All seven patients treated still alive as of last fo...

2 weeks ago - PRNewsWire

Delcath Systems Announces Inducement of Grant Under NASDAQ Listing Rule 5635(C)(4)

NEW YORK , Dec. 16, 2022 /PRNewswire/ -- Delcath Systems, Inc. (Nasdaq: DCTH), an interventional oncology company focused on the treatment of primary and metastatic cancers of the liver, today announc...

1 month ago - PRNewsWire

Delcath Systems Closes Private Placement of $6.2 Million

NEW YORK , Dec. 13, 2022 /PRNewswire/ -- Delcath Systems, Inc. (Nasdaq: DCTH), an interventional oncology company focused on the treatment of primary and metastatic cancers of the liver, today announc...

1 month ago - PRNewsWire

Delcath Systems Announces Private Placement of $6.2 Million

NEW YORK , Dec. 8, 2022 /PRNewswire/ -- Delcath Systems, Inc. (Nasdaq: DCTH), an interventional oncology company focused on the treatment of primary and metastatic cancers of the liver, today announce...

2 months ago - PRNewsWire

Results of a Single Center Study on Delcath's CHEMOSAT® Hepatic Delivery System In the Treatment of Cholangiocarcinoma Published in the Journal Clinical & Experimental Metastasis

Results show that percutaneous hepatic perfusion with CHEMOSAT® is an effective and safe treatment option for patients with advanced cholangiocarcinoma and has the potential to prolong life in patient...

2 months ago - PRNewsWire

Delcath Systems Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)

NEW YORK , Nov. 9, 2022 /PRNewswire/ -- Delcath Systems, Inc. (Nasdaq: DCTH), announces that the Company granted equity awards, previously approved by the Company's Compensation Committee, as a materi...

3 months ago - PRNewsWire

Delcath Systems, Inc. (DCTH) Reports Q3 Loss, Tops Revenue Estimates

Delcath Systems, Inc. (DCTH) delivered earnings and revenue surprises of 12.38% and 10.49%, respectively, for the quarter ended September 2022. Do the numbers hold clues to what lies ahead for the sto...

3 months ago - Zacks Investment Research

Delcath Systems Reports Third Quarter 2022 Results and Provides Business Update

NEW YORK , Nov. 8, 2022 /PRNewswire/ -- Delcath Systems, Inc. (Nasdaq: DCTH), an interventional oncology company focused on the treatment of primary and metastatic cancers of the liver, today reported...

3 months ago - PRNewsWire

Delcath Systems to Host Third Quarter 2022 Results

NEW YORK , Oct. 24, 2022 /PRNewswire/ -- Delcath Systems, Inc. (Nasdaq: DCTH), an interventional oncology company focused on the treatment of primary and metastatic cancers of the liver, announced tod...

3 months ago - PRNewsWire

Delcath Systems to Participate at the H.C. Wainwright 24th Annual Global Investor Conference on September 12 and 13, 2022

NEW YORK , Sept. 1, 2022 /PRNewswire/ -- Delcath Systems, Inc. (Nasdaq: DCTH), an interventional oncology company focused on the treatment of primary and metastatic cancers of the liver, will particip...

5 months ago - PRNewsWire

Delcath Systems, Inc. (DCTH) Reports Q2 Loss, Lags Revenue Estimates

Delcath Systems, Inc. (DCTH) delivered earnings and revenue surprises of -34.09% and 36.49%, respectively, for the quarter ended June 2022. Do the numbers hold clues to what lies ahead for the stock?

6 months ago - Zacks Investment Research

Delcath Systems Reports Second Quarter 2022 Results and Provides Business Update

NEW YORK , Aug. 8, 2022 /PRNewswire/ -- Delcath Systems, Inc. (Nasdaq: DCTH), an interventional oncology company focused on the treatment of primary and metastatic cancers of the liver, today reported...

6 months ago - PRNewsWire

Results of a Multicenter Study on Delcath's CHEMOSAT® Hepatic Delivery System Published in Cardiovascular and Interventional Radiology

Retrospective study in metastatic uveal melanoma patients with liver dominant disease shows an objective response rate of 59.4% and a disease control rate of 89.1%.  The study finds that achieving com...

6 months ago - PRNewsWire

Delcath Systems to Host Second Quarter 2022 Results

NEW YORK , July 27, 2022 /PRNewswire/ -- Delcath Systems, Inc. (Nasdaq: DCTH), an interventional oncology company focused on the treatment of primary and metastatic cancers of the liver, announced tod...

6 months ago - PRNewsWire

Delcath Systems Closes Private Placement of $5.0 Million

NEW YORK , July 20, 2022 /PRNewswire/ -- Delcath Systems, Inc. (Nasdaq: DCTH), an interventional oncology company focused on the treatment of primary and metastatic cancers of the liver, today announc...

7 months ago - PRNewsWire

Delcath Systems Announces Private Placement of $5.0 Million

NEW YORK , July 18, 2022 /PRNewswire/ -- Delcath Systems, Inc. (Nasdaq: DCTH), an interventional oncology company focused on the treatment of primary and metastatic cancers of the liver, today announc...

7 months ago - PRNewsWire

Positive Initial Results from CHOPIN Phase 1b Trial, FOCUS Trial Update and QoL Study Presented at the 2022 ASCO Annual Meeting

Initial results from the Phase 1b portion of the CHOPIN trial of PHP in combination with ipilimumab plus nivolumab in advanced uveal melanoma in seven patients resulted in 85.7% Best Overall Response ...

8 months ago - GlobeNewsWire

Delcath Systems, Inc. (DCTH) Reports Q1 Loss, Misses Revenue Estimates

Delcath Systems, Inc. (DCTH) delivered earnings and revenue surprises of -19.05% and 70%, respectively, for the quarter ended March 2022. Do the numbers hold clues to what lies ahead for the stock?

9 months ago - Zacks Investment Research

Delcath Systems Reports First Quarter 2022 Results and Provides Business Update

NEW YORK , May 10, 2022 (GLOBE NEWSWIRE) -- Delcath Systems, Inc. (Nasdaq: DCTH), an interventional oncology company focused on the treatment of primary and metastatic cancers of the liver, today repo...

9 months ago - GlobeNewsWire

Delcath Announces Poster Presentation at the 2022 ASCO Annual Meeting

NEW YORK, May 09, 2022 (GLOBE NEWSWIRE) -- Delcath Systems, Inc. (Nasdaq: DCTH), an interventional oncology company focused on the treatment of primary and metastatic cancers of the liver, today annou...

9 months ago - GlobeNewsWire

Delcath Systems to Host First Quarter 2022 Results

NEW YORK, April 28, 2022 (GLOBE NEWSWIRE) -- Delcath Systems, Inc. (Nasdaq: DCTH), an interventional oncology company focused on the treatment of primary and metastatic cancers of the liver, announced...

10 months ago - GlobeNewsWire

Delcath Systems to Participate in the Canaccord Genuity Horizons in Oncology Conference

NEW YORK, April 08, 2022 (GLOBE NEWSWIRE) -- Delcath Systems, Inc. (Nasdaq: DCTH), an interventional oncology company focused on the treatment of primary and metastatic cancers of the liver, will part...

10 months ago - GlobeNewsWire

Delcath Systems to Participate in the Lytham Partners Spring 2022 Investor Conference

NEW YORK, March 29, 2022 (GLOBE NEWSWIRE) -- Delcath Systems, Inc. (Nasdaq: DCTH), an interventional oncology company focused on the treatment of primary and metastatic cancers of the liver, announced...

11 months ago - GlobeNewsWire

Delcath Systems, Inc. (DCTH) Reports Q4 Loss, Tops Revenue Estimates

Delcath Systems, Inc. (DCTH) delivered earnings and revenue surprises of 25.81% and 285.38%, respectively, for the quarter ended December 2021. Do the numbers hold clues to what lies ahead for the sto...

11 months ago - Zacks Investment Research